Will GSK complete Phase 3 trials for CMG1A46 by end of 2025? | Binary | | | 2 months ago | |
Will CMG1A46 generate over $500 million in sales within first year? | Binary | | | 2 months ago | |
When will GSK's CMG1A46 achieve blockbuster status by end of 2027? | Categorical | | | 2 months ago | |
Will GSK receive FDA approval for CMG1A46 by end of 2026? | Binary | | | 2 months ago | |
What will be the outcome of GSK's CMG1A46 acquisition by end of 2026? | Categorical | | | 2 months ago | |
Which region will first approve GSK's CMG1A46 by end of 2026? | Categorical | | | 2 months ago | |
Will Chimagen Biosciences receive a milestone payment from GSK by the end of 2024? | Binary | | | 2 months ago | |
Will GSK's newly acquired lupus drug receive FDA approval by the end of 2025? | Binary | | | 2 months ago | |
Will GSK's lupus drug enter Phase 3 trials by October 2025? | Binary | | | 2 months ago | |
What will be the outcome of GSK's lupus drug Phase 2 trials by mid-2025? | Categorical | | | 2 months ago | |
How will GSK's lupus drug affect its market share in autoimmune treatments by 2026? | Categorical | | | 2 months ago | |
What will be the competitive response to GSK's lupus drug acquisition by end of 2025? | Categorical | | | 2 months ago | |
